These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12587950)

  • 1. Comparative study of donepezil and rivastigmine.
    Grossberg G
    Int J Clin Pract; 2003; 57(1):70-1; author reply 71. PubMed ID: 12587950
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 3. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
    Alisky JM
    J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of cholinesterase inhibitors for treatment of Alzheimer disease.
    Hake AM
    Cleve Clin J Med; 2001 Jul; 68(7):608-9, 613-4, 616. PubMed ID: 11453078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
    Ritchie CW; Ames D; Clayton T; Lai R
    Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
    Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
    Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
    Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
    Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
    Stahl SM
    J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of journal advertisements on prescribers of cholinesterase inhibitors.
    Sauer J; Howard R
    Int J Geriatr Psychiatry; 2002 Oct; 17(10):976-8. PubMed ID: 12325061
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
    Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
    Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
    Gasser US; Gasser T
    MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165
    [No Abstract]   [Full Text] [Related]  

  • 15. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
    Schreiter Gasser U; Gasser T
    Fortschr Med Orig; 2001 Nov; 119(3-4):135-8. PubMed ID: 11789125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
    [No Abstract]   [Full Text] [Related]  

  • 18. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistency with rivastigmine and donepezil in a large state medicaid program.
    Singh G; Thomas SK; Arcona S; Lingala V; Mithal A
    J Am Geriatr Soc; 2005 Jul; 53(7):1269-70. PubMed ID: 16108961
    [No Abstract]   [Full Text] [Related]  

  • 20. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
    Castro A; Martinez A
    Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.